BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25034284)

  • 1. Purinergic signaling in liver disease.
    Vaughn BP; Robson SC; Longhi MS
    Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.
    Deaglio S; Robson SC
    Adv Pharmacol; 2011; 61():301-32. PubMed ID: 21586363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological roles of purinergic signaling in the liver.
    Vaughn BP; Robson SC; Burnstock G
    J Hepatol; 2012 Oct; 57(4):916-20. PubMed ID: 22709619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinergic signaling during intestinal inflammation.
    Longhi MS; Moss A; Jiang ZG; Robson SC
    J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.
    Beldi G; Enjyoji K; Wu Y; Miller L; Banz Y; Sun X; Robson SC
    Front Biosci; 2008 Jan; 13():2588-603. PubMed ID: 17981736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purinergic signaling in hepatic disease.
    Velázquez-Miranda E; Díaz-Muñoz M; Vázquez-Cuevas FG
    Purinergic Signal; 2019 Dec; 15(4):477-489. PubMed ID: 31576486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular ATP signaling and clinical relevance.
    Dou L; Chen YF; Cowan PJ; Chen XP
    Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
    Dwyer KM; Kishore BK; Robson SC
    Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
    Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
    J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectonucleotidases in Intestinal and Hepatic Inflammation.
    Vuerich M; Robson SC; Longhi MS
    Front Immunol; 2019; 10():507. PubMed ID: 30941139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic signaling in scarring.
    Ferrari D; Gambari R; Idzko M; Müller T; Albanesi C; Pastore S; La Manna G; Robson SC; Cronstein B
    FASEB J; 2016 Jan; 30(1):3-12. PubMed ID: 26333425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD39-adenosinergic axis in renal pathophysiology and therapeutics.
    Kishore BK; Robson SC; Dwyer KM
    Purinergic Signal; 2018 Jun; 14(2):109-120. PubMed ID: 29332180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synapomorphic features of hepatic and pulmonary vasculatures include comparable purinergic signaling responses in host defense and modulation of inflammation.
    Hanidziar D; Robson SC
    Am J Physiol Gastrointest Liver Physiol; 2021 Aug; 321(2):G200-G212. PubMed ID: 34105986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purinergic Signaling in Liver Pathophysiology.
    Jain S; Jacobson KA
    Front Endocrinol (Lausanne); 2021; 12():718429. PubMed ID: 34456873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic signaling in kidney disease.
    Menzies RI; Tam FW; Unwin RJ; Bailey MA
    Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Roles of Purinergic Signaling in Diabetes.
    Fotino C; Dal Ben D; Adinolfi E
    Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purinergic signalling and immune cells.
    Burnstock G; Boeynaems JM
    Purinergic Signal; 2014 Dec; 10(4):529-64. PubMed ID: 25352330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
    Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
    Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular nucleotide and nucleoside signaling in vascular and blood disease.
    Idzko M; Ferrari D; Riegel AK; Eltzschig HK
    Blood; 2014 Aug; 124(7):1029-37. PubMed ID: 25001468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic transmission in blood vessels.
    Ralevic V; Dunn WR
    Auton Neurosci; 2015 Sep; 191():48-66. PubMed ID: 26004513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.